Heparin Contamination
Heparin Contamination - Related Videos
02:21
Purification of Viral Integrase Using Heparin Affinity Chromatography
0 Views •
2026
Source: Lopez Jr., M. et al. Detection and Removal of Nuclease Contamination During Purification of Recombinant Prototype Foamy Virus Integrase. J. Vis. Exp. (2017)This video demonstrates the procedure for purifying viral integrase from bacterial nuclease contamination using heparin Sepharose column chromatography followed by SDS-PAGE analysis to confirm protein purity.
10:41
Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
0 Views •
Cited by 2 •
2017
A construct encoding TMEM184A with a GFP tag at the carboxy-terminus designed for eukaryotic expression, was employed in assays designed to confirm the identification of TMEM184A as a heparin receptor in vascular cells.
01:16
Contaminants and Errors
0 Views •
2024
Effective sample preparation is crucial for accurate and reliable laboratory analysis. During this process, two significant sources of error can arise: concentration bias from improper sample splitting and contamination caused by methods used to reduce particle size, such as grinding or homogenization. Identifying and minimizing these potential errors is crucial to ensuring the validity of the analysis. Another key consideration is determining the appropriate number of samples required to...
03:40
Heparin Affinity Chromatography-Based Baculovirus Purification: A Technique to Isolate Baculovirus From Insect Cell Supernatant
0 Views •
2025
In this video, we demonstrate the technique to isolate baculovirus from an insect cell supernatant using heparin affinity chromatography. The isolation is facilitated by the affinity between the heparin in the column to the baculovirus envelope glycoprotein.
07:50
Detection and Removal of Nuclease Contamination During Purification of Recombinant Prototype Foamy Virus Integrase
0 Views •
Cited by 10 •
2017
Recombinant prototype foamy virus integrase protein is often contaminated with a bacterial nuclease during purification. This method identifies nuclease contamination and removes it from the final preparation of the enzyme.
FAQs
Residual heparin can enhance antithrombin activity in the specimen. Antithrombin then inhibits thrombin and factor Xa, interfering with the coagulation reactions measured by clot-based assays. This added anticoagulant effect can prolong results such as activated partial thromboplastin time and thrombin time, creating laboratory findings that may not reflect the patient’s actual coagulation status.
These tests assess clot formation through reactions that can be disrupted by heparin-mediated inhibition of thrombin or factor Xa. Consequently, contamination may produce unexpectedly prolonged activated partial thromboplastin time or thrombin time results. Recognizing this pattern is important because the abnormal values may arise from the specimen rather than from genuine anticoagulation or coagulopathy.
Interpretation should consider whether the result is unexpected for the clinical situation and whether the blood came from an anticoagulant-treated intravenous line. A specimen-related explanation becomes more plausible when abnormal clot-based results conflict with the broader clinical assessment. Repeat sampling from a clean peripheral site can help determine whether the initial finding was reproducible.
Avoiding blood collection from an anticoagulant-treated intravenous line reduces the opportunity for heparin to enter the specimen. When an unexpected clot-based result could affect care, obtain a repeat sample from a clean peripheral site. This collection approach improves confidence that the laboratory measurement reflects the patient rather than anticoagulant carryover.
Repeat sampling is appropriate when a clot-based assay is unexpectedly prolonged and the specimen may have been collected through an anticoagulant-treated intravenous line. Drawing from a clean peripheral site provides an independent sample for comparison. The result can help clarify whether the abnormality represents heparin contamination or a genuine anticoagulation or coagulation problem.
Recognizing specimen interference helps prevent clinicians from treating an artifact as true anticoagulation or coagulopathy. Accurate interpretation supports diagnosis, medication monitoring, transfusion decisions, and safe clinical management. In particular, confirming an unexpected result with an appropriately collected specimen can provide a more reliable basis for decisions that depend on clot-based laboratory testing.